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ABSTRACT
Background/aims The life cycle of hepatitis C virus
(HCV) is intimately linked to the lipid metabolism of the
host. In particular, HCV exploits the metabolic machinery
of the lipoproteins in several steps of its life cycle such
as circulation in the bloodstream, cell attachment and
entry, assembly and release of viral particles. However,
the details of how HCV interacts with and influences the
metabolism of the host lipoproteins are not well
understood. A study was undertaken to investigate
whether HCV directly affects the protein composition of
host circulating lipoproteins.
Methods A proteomic analysis of circulating very low-,
low- and high-density lipoproteins (VLDL, LDL and HDL),
isolated from either in-treatment naı¨ve HCV-infected
patients or healthy donors (HD), was performed using
two-dimensional gel electrophoresis and tandem mass
spectrometry (MALDI-TOF/TOF). The results obtained
were further investigated using in vitro models of HCV
infection and replication.
Results A decreased level of apolipoprotein A-I (apoA-I)
was found in the LDL fractions of HCV-infected patients.
This result was confirmed by western blot and ELISA
analysis. HCV cellular models (JFH1 HCV cell culture
system (HCVcc) and HCV subgenomic replicons) showed
that the decreased apoA-I/LDL association originates
from hepatic biogenesis rather than lipoprotein
catabolism occurring in the circulation, and is not due to
a downregulation of the apoA-I protein concentration.
The sole non-structural viral proteins were sufficient to
impair the apoA-I/LDL association. Functional evidence
was obtained for involvement of apoA-I in the viral life
cycle such as RNA replication and virion production. The
specific siRNA-mediated downregulation of apoA-I led to
a reduction in both HCV RNA and viral particle levels in
culture.
Conclusions This study shows that HCV induces
lipoprotein structural modification and that its replication
and production are linked to the host lipoprotein
metabolism, suggesting apoA-I as a new possible target
for antiviral therapy.
INTRODUCTION
Hepatitis C virus (HCV) has a major impact on
public health with an estimated 170 million
infected individuals worldwide, and is the primary
reason for liver transplantation in Western Europe
and the USA. Its infection causes chronic liver
disease eventually leading to cirrhosis and hepato-
cellular carcinoma.1 Several abnormalities of lipid
metabolism such as hypo-b-lipoproteinaemia and
liver steatosis have also been associated with
chronic HCV infection.2 3
Many experimental studies have shown that
the life cycle of HCV is directly linked to lipopro-
teins. In the plasma of HCV-infected patients, the
viral particles are associated with host lipids
and apolipoproteins to form the so-called lipo-viro
particles, mainly present in the range of very low-
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Significance of this study
What is already known about this subject?
< Chronic HCV infection is associated with major
modifications of the host lipid metabolism.
< The lipoprotein machinery is instrumental in
several steps of the life cycle of HCV (ie, blood
circulation, cell attachment and entry, viral
particle assembly and release).
< Circulating very low-density and low-density
lipoproteins (VLDL and LDL) of HCV-infected
patients cause alterations in the lipid metabo-
lism of macrophages.
What are the new findings?
< Chronic HCV infection causes an impaired
association of apolipoprotein A-I (apoA-I) with
the circulating LDL particles of patients.
< The impaired apoA-I/LDL association also
occurs in hepatoma cells infected by HCV cell
culture viral particles or expressing the sole viral
non-structural proteins.
< Impairment of the apoA-I/LDL association
occurs during lipoprotein generation and is
caused by the viral replication stage.
< Downregulation of apoA-I induces significant
impairment of HCV replication, showing that the
replication stage of the viral life cycle also
requires apolipoproteins.
< Downregulation of apoA-I induces a significant
decrease in HCV particle production in cell
culture.
How might it impact on clinical practice in the
foreseeable future?
< This study provides new insight into how HCV
and the host lipoprotein machinery are recipro-
cally influenced.
< This evidence may result in new interest in this
research area which may allow innovative
antiviral strategies to be defined.
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to low-density fractions.4 In particular, immunoprecipitation
and western blot analysis have shown that lipo-viro particles
could contain apolipoprotein (apo) B-100, apoB-48, apoE, apoC-I,
apoC-II and apoC-III.4e6 Notably, HCV infectious particles
generated by the HCV cell culture (HCVcc) system, the only
model which mimics the entire life cycle of the virus,7 have sedi-
mentation velocity and buoyant density profiles similar to those
described for patients with HCV,8 although their molecular
composition has not been fully elucidated.
In addition to CD81, claudin-1 and occludin, the multistep
process of viral cell entry is also mediated by components
of lipoprotein uptake pathways such as glycosaminoglycans,
low-density lipoprotein receptor and scavenger receptor B1.9
HCV cell entry, mediated by a pH- and clathrin-dependent
endocytosis, is increased by apoC-I present in the lipo-viro
particles, which promotes fusion between viral and endosomal
membranes.10 11
Replication of HCV, like all positive-strand RNA viruses,
occurs in association with cytoplasmic membrane vesicles.12
Proteomic analysis of these membrane vesicles recently showed
that they are enriched in several proteins involved in lipid
metabolism and lipoprotein generation (ie, apoB-100, micro-
somal triglyceride transfer protein (MTP), apoE and Acyl-coA
synthetase 3 (ACSL3)).13 Moreover, viral RNA replication has
been shown to be dependent on cholesterol, sphingomyelin and
fatty acid synthetic pathways.14e16
Finally, proteins required for apoB-100-containing lipoprotein
assembly such as apoB-100, apoE, MTP and ACSL3 have been
shown to be necessary for HCV virion production and
infectivity.13 17e22
In view of these findings, it is not surprising that HCVaffects
more than one aspect of lipoprotein metabolism. For instance,
a direct correlation has been observed between the virus and
inhibition of apoB-100 secretion andMTPactivity.23 24 Moreover,
we recently found that the circulating lipoproteins of HCV-
infected patients induce a change in the cellular lipid metabolism
of human monocyte-derived macrophages. In these cells the very
low-density lipoproteins (VLDL) and low-density lipoproteins
(LDL) isolated from HCV-infected patients induce a decrease in
the production of cholesterol ester and triglycerides (TG) and an
increase in TG production, respectively.25 One possible explana-
tion for this observation is that HCV may directly affect the
molecular composition of host circulating lipoproteins.
In this study we attempted to verify this hypothesis by
performing a proteomic analysis of circulating VLDL, LDL and
high-density lipoprotein (HDL) fractions derived from either
HCV-infected patients or healthy subjects using a two-dimen-
sional gel electrophoresis (2-DE) tandem mass spectrometry
(MALDI-TOF/TOF) approach. We found a specific variation in
the LDL fraction of HCV-infected patients which had a lower
apoA-I content. By using HCV cellular models (HCV subge-
nomic replicons and HCVcc system), we demonstrated that the
sole viral replication is sufficient to affect the association of
apoA-I with apoB-100 present in the low-density fraction.
Finally, using a siRNA-based approach, we collected evidence for
a functional role of apoA-I in different steps of the life cycle of
HCV such as RNA replication and viral production in culture.
MATERIALS AND METHODS
Patients
Thirty-one HCV-infected patients were recruited from the
National Institute for Infectious Diseases L Spallanzani. All
participants were in-treatment naïve HCV mono-infected with
either genotype 1 or genotype 3 viruses.
Lipoprotein isolation
Blood samples in EDTA-containing tubes (BD Biosciences, San
Jose, California USA) were obtained from donors after overnight
fasting. Plasma was obtained by centrifugation (10 min, 13003g)
at room temperature. Lipoproteins were isolated according to the
method of Schumaker and Puppione.26 Briefly, plasma was ultra-
centrifuged in a Ti 70 rotor (Beckman) at 403103 rpm for 18 h at
88C.The heavily light-scattering layer of theVLDL fraction on the
top of the tube was collected by glass pipette. Samples were then
brought to a density of 1.063 g/ml with solid potassium bromide
(KBr), ultracentrifuged as above and the LDL fraction collected.
For collection of HDL, samples were brought to a density of
1.21 g/ml with solid KBr and ultracentrifuged as above.
For proteomic analysis, a second density gradient ultracen-
trifugation step was introduced to improve lipoprotein enrich-
ment and purity. KBr was added to the isolated lipoprotein
fractions to give a final density of 1.21 g/ml (VLDL and LDL) or
1.31 g/ml (HDL). These solutions were gently layered with two
sodium bromide solutions (density 1.063 g/ml and 1.006 g/ml
for VLDL; density 1.21 g/ml and 1.063 g/ml for LDL; density
1.24 g/ml and 1.21 g/ml for HDL, respectively) and ultra-
centrifuged as described above. Lipoprotein fractions were
collected from the top of the tube.
Lipoprotein pools used for the first proteomic analysis (shown
in figure 1) were obtained by pooling plasma samples and
isolated as described above. For the second proteomic analysis
(shown in figure 2), lipoproteins were first isolated from a single
donor, then half of the lipoprotein fractions were pooled and
further ultracentrifuged at the appropriate density gradients.
Cell, virus and lipoprotein isolation
Cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum, 100 U/ml penicillin,
100 mg/ml streptomycin and 2 mM L-glutamine (Sigma-Aldrich).
Rep60 cells harbouring the HCV genotype 1b (Con1) subge-
nomic replicon,27 the NNeo/C-5B cell line derived from the
genotype 1b HCV-N28 and the HCV cell culture infection system
HCVcc based on the HCV JFH-1 molecular clone29 have been
described previously. RepBlast cells were derived from Huh7 cells
transfected with the same subgenomic replicon or Rep60 cells in
which theNeomicin gene has been substitutedwith a blasticidine
resistance gene.
For lipoprotein production, 63106 cells were plated in 15 cm
dishes in 20 ml of medium. Huh7.5.1 were infected with JFH1-
derived virus (MOI¼0.1) 2 days before plating. After 3 days of
cultivation the culture media were collected and the lipoproteins
were isolated by the KBr method as described above.
Proteomic analysis, densitometric analysis, western blotting,
ELISA assay, immunoprecipitation, RNA interference, real-time
PCR and HCV RNA copy number quantification are reported in
the online supplement.
RESULTS
ApoA-I levels are decreased in the LDL particles of HCV-infected
patients
The aim of this study was to test whether the circulating
lipoproteins of HCV-infected patients have a different protein
composition from that of healthy donors (HD). Initially we
focused our attention on in-treatment naïve patients infected
with the viral genotype 1. Highly enriched VLDL, LDL and HDL
fractions were obtained from plasma pools (10 HCV-infected
patients and 9 HD) by a sequential two-step ultracentrifugation
procedure using KBr density gradients. After delipidation,
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proteins present in the different lipoprotein fractions were
extracted, resolvedby2-DEandstainedwithSyproRuby (figure 1).
Densitometric analysis showed a statistically significant decrease
in four protein spots, which were identified as isoforms of apoli-
poprotein (apo)A-I by MALDI-TOF/TOF analysis (data not
shown), specifically in the LDL fraction of HCV-infected patients
(central panels; normalised volume spot ratios 2.64-fold between
HD vs HCV-infected patients). No statistically significant differ-
ences in the VLDL and HDL fractions (top and bottom panels,
respectively) were found by densitometric analysis.
In order to confirm this finding by means of another biological
replicate and to measure the variability in apoA-I levels between
individuals, we used a second set of donors, isolating lipoprotein
fractions fromseven in-treatment-naïve genotype 1HCV-infected
patients and 7 HD (table 1). These samples were analysed both in
pools by proteomics and separately by western blotting and 1-DE
coupled to densitometric analysis.
Proteins from pooled lipoproteins were extracted, resolved by
2-DE and stained with Sypro Ruby. Image analysis confirmed the
results obtained with the first set of samples, showing a decrease
Figure 1 Two-dimensional gel
electrophoresis (2-DE) protein pattern of
lipoproteins isolated from patients
infected with hepatitis C virus (HCV) or
healthy donors (HD). Proteins
(300 mg/sample) extracted from VLDL,
LDL and HDL of the first set of donors
(HCV n¼10; HD n¼9) were separated by
2-DE, detected by Sypro Ruby staining
and analysed by MALDI-TOF/TOF mass
spectrometry. ApoE and apoA-I protein
spots, orientation of the pH gradient and
approximate apparent molecular mass
ranges are indicated. apo, apolipoprotein;
HDL, high-density lipoprotein; LDL, low-
density lipoprotein; VLDL, very low-
density lipoprotein.
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in apoA-I levels in the LDL fraction of HCV-infected patients
compared with those of HD. Figure 2A shows the magnification
area of the four apoA-I protein spots in the LDL (top panels) or
HDL (lower panels) preparative gels, as identified by MALDI-
TOF/TOF analysis (data not shown). The more basic isoform
(indicated with p-apoA-I) contains the N-terminal six amino acid
propeptide RHFWQQDEPPQSPWDR, as revealed by the presence
of a strong signal at 2108.98 mass/charge in the mass spectrum
(data not shown); the electrophoretic mobility of the other three
isoforms suggests that they differ in the phosphorylation status.30
Image analysis of these gels showed that the normalised volume
spot ratios of p-apoA-I and apoA-I isoforms were decreased in the
HCV-LDL-like fraction compared with those of HD by 2.4-fold
and 3.0-fold, respectively; again, no differences were found in the
HDL fraction. Western blot analysis for apoA-I confirmed the
proteomics results of both sets of LDL pools (figure 2B).
Since at least some viral particles in the plasma of HCV-
infected patients are associated with apoB-100, increasing their
density in the range of LDL although having a TG/apoB-100
ratio normally defining VLDL, we measured this ratio in the two
sets of pools analysed by proteomics. A slight increase in the
TG/apoB ratio was found in the lipoproteins of HCV-infected
patients compared with HD (0.534 vs 0.480 and 0.833 vs 0.782
for HCV vs HD in pools 1 and 2, respectively), suggesting that
part of our samples could contain viral particles. However, in our
analysis we did not find viral proteins, at least in the amount of
total protein used for the 2-DE preparative gel.
The variability in individual apoA-I levels was measured in
VLDL, LDL and HDL particles by western blot analysis. As
shown in figure 2C, variability among donors was found in
VLDL and LDL fractions, while little variation was observed in
HDL. The major differences in apoA-I levels between the two
groups of samples were seen in the LDL fraction which had
a generally decreased level in the HCV-infected patient group,
thus confirming the results obtained with pools.
The results described so far were obtained by comparing
samples normalised by total protein content. The limited
number of proteins present in lipoprotein particles may render
questionable this normalisation and it could be argued that the
decrease in apoA-I levels observed in HCV-infected patients are
due to a general decrease in the levels of the circulating LDL-like
density fraction. In order to circumvent this problem, taking
into account that each LDL particle contains only one apoB-100
molecule,31 we calculated apoA-I/apoB-100 and apoE/apoB-100
Figure 2 Association of apolipoprotein A-I (apoA-I) with low-density lipoprotein (LDL) is decreased in hepatitis C virus (HCV)-infected patients. (A)
Magnification area of apoA-I protein spots in the two-dimensional electrophoresis gels of LDL (300 mg/sample) or HDL (100 mg/sample), purified from
a second set of donors (HCV n¼7; HD n¼7). pH gradient and approximate apparent molecular mass ranges are indicated. (B) Western blotting for apoA-I
and apoB-100 in the LDL of the two set of pools analysed by proteomics in figures 1 and 2A. (C)Western blotting for apoA-I in VLDL, LDL and HDL fractions
purified individually from donors of the second set of pools analysed in figure 2A. Different amounts of proteins were used: VLDL, 10 mg; LDL, 1 mg; HDL,
0.5 mg. (D) ApoE/apoB-100 and apoA-I/apoB-100 ratio in healthy donors (black columns) and HCV-infected patients (white columns) were determined by
densitometric analysis. Proteins (1 mg) of the LDL were separated by SDS-PAGE, stained with Sypro Ruby and the fluorescence intensities of the protein
bands corresponding to apoE, apoA-I and apoB-100 were measured (see online material for details). Data are reported as mean6SD. *p<0.01. apo,
apolipoprotein; HCV, hepatitis C virus; HD, healthy donors; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.
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ratios by one-dimensional electrophoresis, Sypro Ruby staining
and densitometric analysis. A decrease in the apoA-I/apoB-100
ratio was found in HCV-infected patients, while no significant
differences were found in the apoE/apoB-100 ratio (figure 2D).
Moreover, since no significant differences in the apoB-100 levels
were found by densitometric analysis (not shown) or by western
blotting (figure 2B), we conclude that, in HCV-infected patients,
the reduction in apoA-I is due to a specific impairment of the
association of apoA-I with LDL-like particles rather than
a general decrease in the level of these lipoproteins.
We then investigated whether this observation could be
extended tootherHCVgenotypes.TheLDL levels of in-treatment-
naïve patients chronically infected with HCV genotype 3 (ie, the
most steatogenic viral genotype) were analysed. Lipoproteins
were isolated from the plasma of seven patients, apoA-I and
apoB-100 levels measured by ELISA assays, the apoA-I/apoB-100
ratios were calculated and then compared with those of patients
infected with HCV genotype 1 or HD. As shown in figure 3, the
average apoA-I/apoB-100 ratio of patients infected with HCV
genotype 3 was significantly lower than those of patients with
HCV genotype 1 and HD. Again this decrease was due to a lower
apoA-I level (figure 3; central panel).
Taken together, these results show that, during chronic
HCV infection, the association of apoA-I with circulating LDL
particles is specifically impaired.
HCV replication affects the intracellular apoA-I association with
LDL
LDL is mainly derived from plasma VLDL catabolism. However,
cell experiments and studies in animalmodels support the concept
that the liver is also capable of producing apoB-100-containing
lipoproteins of IDL/LDL densities.32e35 Using the HCV cellular
models, we determined whether the presence of the virus directly
affects the association of apoA-I with LDL.
First, we used the JFH1 HCVcc (genotype 2a) which generates
infectious HCV particles in the Huh7-5.1 hepatoma cell line,
thus recapitulating the complete viral life cycle.7 After 4 days of
cultivation the LDL released in the culture medium by either the
parental or JFH1-infected cells were isolated using the standard
KBr ultracentrifugation method. As shown in figure 4A, the
presence of apoA-I was specifically reduced in the LDL fraction
of JFH1-infected cells (top panel) while its level was unchanged
in the culture medium and intracellularly. These results indicate
that, in hepatocytes, HCV infection induces an impairment in
the association of apoA-I with nascent LDL rather than
a reduction in apoA-I synthesis or release.
In order to determine which stage of the HCV life cycle affects
the apoA-I/LDL association, we used cells carrying the subge-
nomic HCV replicons which recapitulate exclusively the intra-
cellular steps of RNA replication.36 Tominimise clone-specific and
drug-specific effects, two different Huh7-derived cell lines were
used: rep60 cells, which are resistant to G418 and derived from
single cell cloning,27 and repBlast cells, which are resistant to
blasticidine and derived from a mixed population (unpublished);
the two cell lines share the same HCV subgenomic replicon
(genotype 1b). ApoA-I levels were measured in LDL-like density
lipoproteins, in culture medium and whole cell extracts by
western blotting. Figure 4B shows that compared with the
parental cell lineHuh7, both rep60 and repBlast cells had decreased
apoA-I content specifically in the LDL-like density lipoproteins.
These results were also confirmed by ELISA assays, which quan-
tified an average of 50% reduction in the apoA-I/apoB-100 ratio in
Table 1 Characteristics of donors
HCV genotype 3* HCV genotype 1* HD*
Age (years) 50.5765.10 53.4367.89 35.4369.54
Sex (% male) 71.4 71.4 71.4
HCV RNA (IU/mL) 4.316.91164.233.514 3.745.50162.962.205 ND
ApoA-I (mg/dL) 140.57643.17 145.66622.05 143.60618.79
ApoB-100 (mg/dL) 75.43626.81 75.44622.05 77.50624.55
Chol-Total (mg/dL) 156.57635.93 147.00629.46 158.86626.42
Chol-HDL (mg/dL) 47.43623.44 48.86616.65 46.8668.32
Chol-LDL (mg/dL) 100.17633.33 79.57620.60 93.43626.99
Triglycerides (mg/dL) 91.26637.70 92.14634.50 91.00652.01
ALT (mU/mL) 89.67641.24y 92.50686.29y 23.43615.30
gGT (mU/mL) 38.57620.02 97.67657.51z 21.7165.38
Glucose (g/L) 0.9760.10 0.9760.13 0.9960.07
*n¼7.
yp<0.005 vs HD.
zp<0.001 vs HD and p<0.05 vs genotype 3.
ALT, alanine transaminase; apoA, apoB, apolipoprotein A and B; Chol, cholesterol; gGT, g-glutamyl transferase; HCV, hepatitis C virus;
HD, healthy donors; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Figure 3 Association of apolipoprotein AI (apoA-I) with low-density lipoprotein (LDL) is decreased in patients infected with hepatitis C virus (HCV)
genotypes 1 and 3. LDL fractions were isolated individually from either in-treatment-naı¨ve HCV-infected patients (genotype 1, n¼7; genotype 3, n¼7)
or healthy donors (HD, n¼7). ApoA-I and apoB-100 amounts were determined by specific ELISA assay and reported as mean6SD. *p<0.02 vs healthy
donors.
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both cell lines (figure 4C, left panel). This was mainly caused by
a decrease in the level of apoA-I (figure 4C, central panel) rather
than an increase in the apoB-100 content (figure 4C, right panel).
We then investigated whether the decreased apoA-I level was
associated with apoB-100-containing lipoproteins rather than
with non-apoB-100 lipid-rich particles. We immunoprecipitated
apoB-100 and performed western blotting against apoA-I.
Unfortunately, all the anti-apoA-I antibodies tested (n¼6) cross-
reacted with some component of the protein G or A released in
the immunoprecipitated samples (data not shown and NS band
in figure 4D), so we immunodepleted apoB-100 in the LDL-like
density lipoproteins generated by Huh7 and repBlast cells and
tested the unbound material for the presence of apoA-I. As
shown in figure 4D, after two rounds of apoB-100 immuno-
precipitation, apoA-I was not detected in the flow-through (ie,
apoB-100-depleted material), which suggests that all the apoA-I
present in the LDL-like density particles produced by the two
cell lines are associated with apoB-100. This result therefore
strengthens the hypothesis that HCV affects the association of
intracellular apoA-IwithnascentapoB-100-containing lipoproteins
rather than apoA-I detachment upon secretion.
Taken together, these results show that HCV affects the
association of intracellular apoA-I with nascent LDL-like density
lipoproteins, a specific phenomenon that could not be ascribed
to a general reduction in apoA-I. Notably, the sole viral replica-
tion apparatus (ie, non-structural (NS) proteins) was sufficient
to induce this impairment.
ApoA-I downregulation affects HCV replication and virion
production
The results indicating that HCV NS proteins affect the associ-
ation of apoA-I with LDL recall previous reports showing
a direct interaction between apoA-I with NS5A in vivo and in
vitro.37 38 The pivotal role of NS5A in viral replication and virus
production led us to speculate an involvement of apoA-I in these
processes.
In order to test this hypothesis, apoA-I expression was
silenced by specific small interfering RNA (siRNA). Three
siRNAs targeting different regions of apoA-I were tested and the
most efficient apoA-I downregulator was selected (data not
shown) and used for the analyses.
To analyse a possible role for apoA-I in HCV replication, rep60
and repBlast cells were transfected with either the siRNA
targeting apoA-I or a scrambled control siRNA containing
a similar GC content (CTR-L). Only apoA-I siRNA significantly
reduced the protein and mRNA levels of apoA-I, assessed 3 and
6 days after transfection (figure 5A and 5B), while it did not
change the level of apoE (figure 5A) and did not cause a general
cellular toxicity as assessed by total RNA and protein synthesis
(data not shown).
Interestingly, in both rep60 and repBlast cells, apoA-I down-
regulation resulted in a significant decrease in the levels of NS5A
protein (figure 5A) and HCV RNA (figure 5B) 6 days after
transfection with only a slight effect 3 days after transfection, as
measured by western blotting and quantitative real-time PCR,
Figure 4 Expression of hepatitis C virus (HCV) non-structural (NS) proteins is sufficient to impair the association of apolipoprotein A-I (apoA-I) with
nascent low-density lipoprotein (LDL). Western blot analysis of apoA-I in the low-density fraction (LDL), conditional medium (CM) and whole cell
extract (WCE) of (A) parental (Huh7.5.1) and JFH1-infected cells or (B) parental (Huh7) and sub-genomic replicon-carrying cells rep60 and repBlast.
Different amounts of samples were analysed in the LDL-like density lipoproteins (20 mg), CM (2 ml) and WCE (10 mg). NS3 and NS5A proteins were
used as controls for the presence of viral proteins; tubulin was used as loading control. One representative experiment out of three is shown. (C) Levels
of apoA-I and apoB-100 in the LDL fraction produced by rep60, repBlast and Huh7 cells were measured by ELISA assay. Four experiments were
performed and reported as mean6SD. *p<0.05; #p<0.02 vs Huh7 cells. (D) LDL-like density fraction isolated from Huh7 (H) and repBlast (R) cells were
immunodepleted of apoB-100 by two consecutive rounds of immunoprecipitation. LDL-like density lipoproteins (input), apoB-100-immunoprecipitated
(IpapoB-100) and apoB-immunodepleted samples were analysed for the presence of apoA-I and apoB-100 by western blotting. IpapoB-100 shows a NS
band close to the apoA-I signal due to a component of protein G (protein G lane). One representative experiment out of three is shown.
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respectively. The same results were obtained in the full-length
genomic replicon-carrying cells transfected with the specific
apoA-I siRNA 6 days after transfection (figure 5C and 5D).
Overall, these data suggest a functional role for apoA-I in
HCV replication.
Next, we tested whether apoA-I is involved in the production
of infectious HCV particles by hepatocytes. To this aim, Huh7
cells were transfected with either apoA-I-specific siRNA or
CTR-L siRNA and, after 24 h, infected with HCV at MOI¼0.1
for 2 h. The effect of apoA-I siRNA on HCV production was
assessed by quantifying the viral RNA released in the medium at
different time points after infection. In control cells transfected
with the CTR-L siRNA, the HCV RNA copy number increased
by $100-fold during the 4 days of culture (figure 6A). In cells
transfected with apoA-I siRNA, HCV production was signifi-
cantly reduced (ranged 70e90%), starting from the second day
after infection (figure 6A). These reduced levels of HCV RNA
copy number were similar to those obtained by cells transfected
with apoB-100 siRNA (reduction of 85e95%) that we used as
a control for the inhibition of HCV viral production (data not
shown).13 17 19 21 Importantly, the decreased amount of HCV
RNA present in the medium of apoA-I siRNA-treated cells is not
caused by the inhibition of viral RNA synthesis; in these cells
the intracellular HCV RNA levels remained unaffected from day
1 to day 3 after infection (figure 6B). However, it is worth noting
that, at day 4 after infection, the intracellular HCV RNA level
was decreased by z50%, thus confirming the results obtained
with the replicon-carrying cells. The intracellular apoA-I mRNA
levels were significantly decreased over the duration of the
experiments in the apoA-I siRNA-treated cells (figure 6C).
Finally, we analysed the infectivity of the HCV virions
generated by HCV-infected and siRNA-transfected Huh7 cells
(ie, 4 days after infection) by infecting naïve Huh7.5.1 cells and
measuring, after 48 h, the intracellular HCV RNA copy number
by RT-qPCR. Huh7.5.1 cells infected with HCV generated by
apoA-I-silenced cells showed a reduction of about 70% in the
amount of intracellular HCV RNA compared with those
infected with HCV produced by CTR-L siRNA-transfected cells
(figure 6D), consistently with decreased HCV copy numbers
measured in the culture medium (figure 6A).
Taken together, these data show that apoA-I function influ-
ences several steps of the HCV life cycle such as replication and
virion production.
DISCUSSION
HCV gene expression has been associated with lipid dysmetabo-
lism in both humans and animals.39e41 Moreover, there is
increasing evidence to indicate that the virus uses the host lipo-
protein machinery for its life cycle and dissemination.42 Analysis
of the quality and quantity of lipoprotein componentsmay reveal
important information about the mechanisms responsible for
virus-mediated lipid dysmetabolism. The recent development of
ionisation methods coupled to mass spectrometry has allowed an
in-depth biochemical analysis of the proteins associated with
lipoproteins. In this study, bymeans of a 2-DEMALDI-TOF/TOF
proteomic approach, we compared the protein composition of the
main subclasses of circulating lipoproteins isolated from HCV-
infected patients with those from healthy subjects.
The main finding of our studies was the identification of an
LDL-specific reduction of apoA-I in HCV-infected patients,
showing for the first time a lipoprotein structural alteration
induced by this virus. This variation has not been observed
previously, possibly because the parameters usually monitored in
clinical studies are total plasma lipids and apolipoprotein
concentrations and not the molecular composition of the lipo-
protein particles. Indeed, in our analysis, no significant differences
in the total lipid concentration or in total circulating apoA-I levels
were measured between HCV-infected patients and HD (table 1).
ApoA-I, themajor structural protein of theHDL,mediatesmost
of the anti-atherogenic properties of these lipoproteins. It has been
described as protecting against the development of premature
atherosclerosis and acting as an anti-inflammatory agent.43 44
Conversely, to the best of our knowledge, its role in the physiology
of VLDL/LDL is as yet unknown, probably because it has only
recently been associated with VLDL and LDL by proteomic anal-
yses.45 46 Since we recently found that lipoproteins derived from
HCV-infected patients induce altered cellular lipid metabolism,25
Figure 5 Apolipoprotein A-I (apoA-I) is required for replication of
hepatitis C virus (HCV) in the replicon systems. (A,B) Downregulation of
apoA-I expression in rep60 and repBlast cells was obtained by specific
siRNA. (A) Western blotting analysis for apoA-I, NS5A and apoE was
performed at 3 and 6 days after transfection in cells untransfected (/) or
transfected with either scrambled control siRNA (CTR-L) or siRNA
targeting apoA-I. (B) Levels of apoA-I mRNA and HCV RNA were
measured by quantitative real-time PCR (qPCR) in cells transfected with
CTR-L (white bars) or apoA-I (black bars) siRNA. (C,D) Downregulation
of apoA-I expression in full-length genomic replicon harbouring cells by
siRNA. (C) Western blotting analysis for apoA-I and NS5A was
performed 6 days after transfection as described in (A). (D) Levels of
apoA-I mRNA and HCV RNA were measured as described in (B).
Western blotting analysis of one representative experiment out of at
least four is shown; qPCR values were normalised to L34 mRNA levels
and reported as fold changes relative to control samples (mean6SD of
at least four experiments).
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it is tempting to speculate that the decreased apoA-I level could
have a role in this dysmetabolism. Experiments on the biogenesis
and on the metabolic properties of apoB-100-containing lipopro-
teins in the absence of apoA-I, either in presence or absence of
HCV proteins, are necessary to test this hypothesis.
LDL are derived mainly from VLDL catabolism in the circu-
lation, but they can also be generated by the liver.32e35 Although
it is known that the exchange of apolipoproteins among lipo-
protein particles and interconversion of particles occurs in the
plasma compartment, our observations indicate that the
HCV-induced decreased association of apoA-I with LDL probably
has a cellular origin. In fact, among the apoA-I isoforms found to
be decreased in the LDL of HCV-infected patients, mass spec-
trometry identified the intracellular p-apoA-I isoform (figure 2A),
which carries the six amino acid propeptide known to be removed
soon after the release of apoA-I in the circulation.47
Notably, we also observed the HCV-associated LDL-specific
reduction in apoA-I in cellular models. This has a number of
implications: (1) it supports the hypothesis that the virus-
induced decrease in the apoA-I level in apoB-100-containing
lipoproteins derives from their biogenesis rather than lipoprotein
catabolism occurring in the circulation; (2) it provides a robust
correlation between the virus and the LDL altered composition,
well beyond the conclusions drawn by the limited numbers of
HCV-infected patients analysed in this study; (3) it indicates
that, as the secreted or intracellular apoA-I level was unaffected,
the impaired apoA-I/LDL association is not due to a general
downregulation of apoA-I; (4) the results obtained with subge-
nomic replicon-carrying cells, which recapitulate only the viral
RNA replication model, indicate that the sole NS viral proteins
are sufficient to impair the apoA-I/LDL association.
In the light of this latter point, it is tempting to speculate that
LDL biogenesis and viral replication share elements which could
be limiting factors for both processes. Common site and bridging
molecules between viral replication and LDL biogenesis are
indeed conceivable. In particular, the HCV replication complex
induces the formation of a membranous web that derives from
endoplasmic reticulum membranes48 where the lipoprotein
assembly starts to take place.49 Most importantly, a direct
interaction between NS5A and apoA-I has been reported to
occur both in vitro and in vivo.37 38
The description of the possible interactions occurring between
the platforms driving apoB-100-containing lipoprotein biogen-
esis and viral replication is hampered by the paucity of infor-
mation regarding these processes. We therefore attempted
directly to gather functional evidence on apoA-I involvement in
viral replication. We found that the specific downregulation of
apoA-I by siRNA in the two subgenomic replicon-carrying cells
(rep60 and repBlast) induced a significant reduction in both
HCV RNA and NS5A protein levels.
The membranous web, a membrane alteration of the endo-
plasmic reticulum induced by HCV, is the site of viral RNA
synthesis. However, it has been reported that, in the presence of
HCV core protein, viral replication is also present on lipid drop-
lets.50 Our data, obtained with both a genomic replicon non-
infectious system (figure 5C) and with HCVcc (figure 6), suggest
that apoA-I is also necessary in the presence of viral structural
proteins, thus indicating that apoA-I function is required forHCV
replication in vitro. Interestingly, it has been reported that, in liver
biopsies of HCV-infected patients, viral RNA could be found
associated with apoA-I,51 indicating that this apolipoprotein
could also play a role in viral replication in vivo.
Since in the absence of apoA-I expression viral replication is
significantlyhampered starting 5e6 days after siRNAtransfection
while a considerable reduction in apoA-I protein levels is observed
as early as 2 days after transfection, it is likely that apoA-I acts
Figure 6 Apolipoprotein A-I (apoA-I) is
required for production of hepatitis C
virus (HCV) in culture. Huh7 cells were
transfected with control siRNA (CTR-L)
or apoA-I siRNA and, after 24 h, infected
with HCV at an MOI of 0.1 (as described
in the online supplement). The RNA
present in the culture medium or
intracellularly was collected at different
time points. Results from three
independent experiments are shown. (A)
HCV RNA copy number present in the
culture medium of CTR-L or apoA-I
siRNA-treated cells, as indicated, was
determined by RT-qPCR using the vector
coding for the HCV JFH-1 genome as
standard curve (see online supplement)
and reported as mean6SD fold changes
relative to CTR-L siRNA-treated cells on
day 1 after infection. (B) Intracellular
levels of HCV RNA of CTR-L or apoA-I
siRNA-treated cells, as indicated, were
measured by RT-qPCR, normalised for
L34 mRNA levels and reported as
mean6SD fold changes relative to CTR-L
siRNA-treated cells on day 1 after
infection. (C) Levels of apoA-I mRNA
were measured by RT-qPCR in cells
transfected with CTR-L (white bars) or apoA-I (black bars) siRNA. qPCR values were normalised to L34 mRNA levels and reported as mean6SD fold
changes relative to control samples at each day of culture. (D) Infectivity of HCV viral particles generated, after 4 days of culture, by HCV-infected Huh7
cells transfected with either CTR-L (white bars) or apoA-I (black bars) siRNA. Naı¨ve Huh7.5.1 cells were infected by HCV particles and their intracellular
viral RNA levels were measured after 48 h by RT-qPCR. qPCR values were normalised to L34 mRNA levels and reported as fold changes relative to
control samples (mean6SD of three independent experiments).
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indirectly in the replication complex through other molecules
involved in this process. However, we can recall as a possible
mechanism the apoA-I function in intracellular cholesterol
efflux,52 which is known to be important in the HCV life cycle.53
Further evidence is needed to confirm this hypothesis and possibly
to elucidate the specific molecular mechanism.
In addition to this role in HCV replication, we found that
apoA-I also has a role in the formation and/or release of viral
particles. ApoA-I joins the other members of the lipoprotein
family (apoB-100, apoE, MTP or ACLS3) known to be involved
in HCV production,13 17e22 which suggests that lipoproteins, in
addition to viral assembly, release and infectivity, could also have
an active role in viral replication, strengthening the link between
HCV and the lipoprotein synthesis and secretion pathway.
In conclusion, our study provides an insight into the mecha-
nisms that regulate the relationship between HCV and the
metabolism of the host lipoproteins, and suggests that apoA-I
may be a possible target for antiviral therapy.
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